Oct 3, 2026
Z-basivarsen shows sustained benefits in myotonic dystrophy type 1 trial
An investigational drug, z-basivarsen, demonstrated sustained improvements in myotonia, motor function, and strength in patients with myotonic dystrophy type 1, according to analysis from the ACHIEVE trial. The findings suggest potential therapeutic benefits for this genetic neuromuscular disorder.
2 sources
00